Philippe Vroman

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer

Sandrina Lambrechts, Diether Lambrechts, Evelyn Despierre et al. · BMC Pharmacology and Toxicology · 2015 · 56 citations · Full text

Medicine, Genetics, Oncology +17

Does Gel Affect Cytology or Comfort in the Screening Papanicolaou Smear?

M. Gilson, Angel N. Desai, Gabriella Cardoza-Favarato et al. · The Journal of the American Board of Family Medicine · 2006 · 29 citations · Full text

Medicine, Infectious Diseases, Microbiology +16

Weekly Docetaxel in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Pol Specenier, Marika Rasschaert, Philippe Vroman et al. · American Journal of Clinical Oncology · 2010 · 19 citations

Medicine, Oncology, Pharmacology +11

Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma

Johnny Duerinck, Paul M. Clément, Frank Bouttens et al. · Journal of Neurology · 2015 · 13 citations

Medicine, Neurosurgery, Oncology +13